Fluticasone Propionate And Salmeterol Powder
Product Images NDC 70518-3968

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 70518-3968). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This text provides important information about a medication containing Fluticasone Propionate and Salmeterol. It is an inhalation powder with a quantity of 60 blisters, each containing 250mcg/50mcg. The medication is manufactured by Hikma Pharma in Amman, Jordan. It is important to store the medication in a dry place away from direct heat or sunlight. The directions for use can be found in the package insert. Additionally, the medication is to be stored at 20-25°C and can have limited excursions to 15.30°C. This specific package was repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Figurec.jpg (Figurec)

FDA Label Image

Fluticasone-propionate-chemical.jpg (Fluticasone Propionate Chemical)

FDA Label Image

Figure-5-08172021.jpg (Image 03)

This text contains information related to different inhalation powders including Fluticasone Propionate and Salmeterol with different concentrations. It also mentions a placebo and provides data on the % change in FEV (Forced Expiratory Volume) in relation to the use of these inhalation powders. The text seems to be some sort of study or medication comparison.*

FDA Label Image

Figure-4.jpg (Image 04)

This dataset shows the results of a study comparing the effectiveness of Fluticasone Propionate and Salmeterol Inhalation Powder to Salmeterol and Placebo in improving lung function. The study involved participants using the inhalers twice daily. The results indicate that the group using Fluticasone Propionate and Salmeterol Inhalation Powder showed improvements in forced expiratory volume (FEV) compared to the Salmeterol and Placebo groups. This data points to the potential advantages of using Fluticasone Propionate and Salmeterol Inhalation Powder for lung conditions.*

FDA Label Image

Figure-1a (Image 05)

This text provides data from a study comparing the effectiveness of Fluticasone Propionate and Salmeterol Inhalation Powder, Fluticasone Propionate alone, Salmeterol alone, and a Placebo on certain parameters over a period of 12 weeks. The study involves using these medications at different dosages twice daily. The results show the percentage of improvement in the subjects' conditions over the study period.*

FDA Label Image

Figure-2.jpg (Image 06)

This chart shows the percentage change in FEV4 for different treatment groups on the first treatment day. The treatments evaluated include Fluticasone Propionate and Salmeterol Inhalation Powder, Salmeterol alone, Fluticasone Propionate alone, and Placebo. The data provides insights into the effects of these treatments on lung function.*

FDA Label Image

Figure-3a (Image 07)

FDA Label Image

Salmeterol-xinafoate-chemical.jpg (Salmeterol Xinafoate Chemical)

FDA Label Image

Ww-image-2.jpg (Ww Image 2)

FDA Label Image

Ww-image-4.jpg (Ww Image 4)

FDA Label Image

Ww-image-5.jpg (Ww Image 5)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.